Articles

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

How Financialization Has Impacted the US Healthcare System

Videos

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

The Evolving Role of PBMs: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group

Data presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium show first-line Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Radioligand Therapy Found to Improve Survival, Disease Progression in Advanced GEP-NETs

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives. 

In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate Price 

Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.

FDA to Evaluate Premarket Approval Application for TTFields in Non-Small Cell Lung Cancer

In an interview with  Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group

Pivmecillinam (Pivya) has a clinical cure rate of 95% in uncomplicated urinary tract infections and is recommended as a first-line option for treatment in many countries.

Antibiotic for Uncomplicated Urinary Tract Infections Granted FDA Priority Review

Data show daily oral dosing of NX-5948 in patients with relapsed or refractory B-cell malignancies experienced a clinical benefit across dose ranges from 50 mg to 200 mg.

Novel BTK Inhibitor Granted FDA Fast Track Designation for SLL, CLL

The predicted value is largely driven by manufacturers' prioritization of brand protection. 

Report: Track-and-Trace Solutions Market Anticipated to Hit $9.8 Billion by 2028 

Bloomlife’s MFM-Pro enables healthcare providers to measure maternal and fetal heart rate in the patient's home or clinic.

News